Drugs / Indium-111-DOTA-Labetuzumab-IRDye800CW
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03699332 | Dec 2018 → Mar 2021 | carcinoma, colorectal cancer, peritoneal carcinomatosis | Radboud University Medical Center | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Indium-111-DOTA-Labetuzumab-IRDye800CW | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03699332 ↗ |
| Known as | [111In]In-DOTA-labetuzumab-IRDye800CW | “In this study (ClinicalTrials.gov NCT03699332) we describe the results of a phase I clinical trial evaluating [111In]In-DOTA-labetuzumab-IRDye800CW, a dual-labeled...” PMID 35551444 ↗ May 2022 |
| Route | Intravenous | “Patients receive a single intravenous dose of Indium-111-DOTA-Labetuzumab-IRDye800CW.” NCT03699332 ↗ |